Baseline characteristics at CAR-T MTB of R/R MCL after brexu-cel failure (relapsed set)
| Baseline Characteristics . | MCL relapsed set, N = 61 . | |
|---|---|---|
| Sex, male | 54 | 88.5% |
| Age, median (min; max) | 66.0 (39; 83) | |
| Age ≥65 years | 35 | 57.4% |
| Age >75 years | 2 | 3.3% |
| ECOG PS | ||
| 0-1 | 54/57 | 94.7% |
| ≥2 | 3/57 | 5.3% |
| Bulk disease >5 cm | 34/59 | 57.6% |
| MIPI risk | ||
| Low risk (<5.7) | 13/53 | 24.5% |
| Intermediate risk (5.7-6.2) | 21/53 | 39.6% |
| High risk (≥6.2) | 19/53 | 35.8% |
| Ki-67 of ≥30% | 32/42 | 76.2% |
| Blastoid variant | 18/57 | 31.6% |
| TP53 mutation | 13/43 | 30.2% |
| LDH greater than normal | 35/59 | 59.3% |
| CRP of >30 mg/L | 16/60 | 26.2% |
| Number of previous lines | ||
| Median (min; max) 3 (2; 8) | ||
| Detail of previous lines | ||
| 2 | 16 | 26.2% |
| 3 | 26 | 42.6% |
| ≥4 | 19 | 31% |
| Refractory status∗ | 37/58 | 63.8% |
| POD24 status positive | 51/60 | 83% |
| Progressive disease after bridge† | 25/57 | 44.5% |
| Baseline Characteristics . | MCL relapsed set, N = 61 . | |
|---|---|---|
| Sex, male | 54 | 88.5% |
| Age, median (min; max) | 66.0 (39; 83) | |
| Age ≥65 years | 35 | 57.4% |
| Age >75 years | 2 | 3.3% |
| ECOG PS | ||
| 0-1 | 54/57 | 94.7% |
| ≥2 | 3/57 | 5.3% |
| Bulk disease >5 cm | 34/59 | 57.6% |
| MIPI risk | ||
| Low risk (<5.7) | 13/53 | 24.5% |
| Intermediate risk (5.7-6.2) | 21/53 | 39.6% |
| High risk (≥6.2) | 19/53 | 35.8% |
| Ki-67 of ≥30% | 32/42 | 76.2% |
| Blastoid variant | 18/57 | 31.6% |
| TP53 mutation | 13/43 | 30.2% |
| LDH greater than normal | 35/59 | 59.3% |
| CRP of >30 mg/L | 16/60 | 26.2% |
| Number of previous lines | ||
| Median (min; max) 3 (2; 8) | ||
| Detail of previous lines | ||
| 2 | 16 | 26.2% |
| 3 | 26 | 42.6% |
| ≥4 | 19 | 31% |
| Refractory status∗ | 37/58 | 63.8% |
| POD24 status positive | 51/60 | 83% |
| Progressive disease after bridge† | 25/57 | 44.5% |